PMID: 42224Oct 20, 1979

A double blind cross-over study with mepindolol-sulfate in patients with coronary heart disease (author's transl)

Wiener medizinische Wochenschrift
J BonelliG Kaik


The effect of mepindolol-sulfate (2 x 2.5 mg) was tested in 20 patients with coronary heart disease in a controlled study against placebo resp. propranolol (3 x 40 mg). 1. The frequency and intensity of anginal attacks were reduced significantly under mepindolol-sulfate therapy.-- 2. There was a significant improvement of ergometric exercise tolerance under mepindolol-sulfate therapy.--3. Additionally a reduction of ST-depression in ECG was found under mepindolol-sulfate.--4. In patients with coronary heart disease the clinical effect of mepindolol-sulfate in a daily dose of 2 x 2.5 mg was equal to propranolol in a daily dose of 3 x 40 mg.

Related Concepts

Myocardial Contraction
Anginal Attack
Coronary Arteriosclerosis
Drug Evaluation
Respiratory, Thoracic and Mediastinal Disorders

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.